Meet Paul Tran, Founder and CEO of Rocketship DTC Brand MANSCAPED™
13.4.2021 16:00:00 EEST | Business Wire | Press release
Today, MANSCAPED™, the global leader in men’s below-the-waist grooming, is cracking the code behind the company’s success with an exclusive introduction to its Founder and CEO, Paul Tran. From early beginnings to ongoing endeavors, Paul maintains a steadfast dedication to creativity, long-term thinking, and lifelong learning. These are just a few key takeaways as we get acquainted with the man leading MANSCAPED’s massive movement.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005280/en/
Paul Tran founded MANSCAPED in 2016 with a mission of moving men forward all over the world. (Photo: Business Wire)
A Born Entrepreneur. Born in Vietnam, Paul grew up with little, but with a big outlook on life. Although he experienced adversity at a young age, and as a first-generation immigrant in America who didn’t speak English, he reflects on his upbringing very fondly. Having nothing and coming from nothing ingrained a sense of ambition in Paul, driving him to make the most of any opportunity and practice empathy always.
After settling in New York, his vocabulary soon expanded beyond “hi” and, albeit the only Asian kid in school, he assimilated quickly among his peers and made friends due to his unassuming demeanor, self-awareness, and good nature. A born entrepreneur, Paul recalls one of his earliest memories from elementary school was when he hosted a raffle every Friday. It was a basic concept with no more than nickels on the table, but a weekly activity his classmates raved about and looked forward to. The popular game enhanced their lives unknowingly, while reaffirming Paul’s inner creative spirit.
Fast forward several years, this undeniable self-starter put himself through college at the University of Southern California where he studied at Marshall School of Business and Viterbi School of Engineering. He parlayed his education into his next ventures, which included launching and selling multiple businesses. One was a revolutionary science-backed skincare brand that provides a non-surgical solution for wrinkles and stretch marks. This was Paul’s first company that tackled taboos in the beauty space, but it most certainly wouldn’t be the last.
The MANSCAPED Movement. Paul launched MANSCAPED in 2016 with a vision of driving the movement that changes the face of men’s grooming. By focusing on the needs of what has, for too long, been a sensitive and often stigmatized subject, MANSCAPED has successfully untapped a vast market of male consumers. The brand not only provides premium tools and products for proper grooming but moves men forward by unlocking their confidence and allowing them to be the best versions of themselves. Paul lives by this mission every single day and envisions a world in the future where MANSCAPED plays a significant part in people’s lives all over the world.
Beyond seeing this vision materialize in real life, Paul thrives on working with his supportive and talented team. He is humble at his core, often highlighting teammates for execution and successes rather than taking any credit. This level of humility is understated but significant, as it flows deep into the organization. As CEO, Paul’s responsibilities are many. He loves overseeing the brand’s innovation and technology as a superior technician himself. He also spearheads the company’s direction as a brilliant strategist and constantly works to further establish MANSCAPED as an employer brand that puts company culture and people first. Ensuring that everyone feels valued, included, and appreciated for their efforts is extremely important to him.
Although at the helm of the entire MANSCAPED Family, Paul is a self-described introvert at heart and enjoys spending time in small groups where we can have meaningful conversations and directly care for his colleagues. His intelligent presentations, inspiring words, and witty humor are experienced by all 150 employees during MANSCAPED’s biweekly company-wide meetings. Calendar notifications go from mundane reminders to sparks of joy on these days. As a winner of Inc. Magazine’s Best Workplaces in 2020, MANSCAPED is a workforce of individuals who are as happy as they are grateful for the environment Paul has created.
A Philanthropic Future. When he gets a sliver of time outside of MANSCAPED, Paul feeds his soul by spending time with his wife and two young children. This dedicated father and loving husband shares a special intellectual curiosity with his family. When their conversations run the gamut, Paul always walks away with a fresh perspective on life and appreciation for how far he has come. His deep-rooted desire to give back and commitment to social responsibility are fundamentals he has brought to MANSCAPED, as well as beliefs he lives by. Just one of his lifelong philanthropic goals is setting up his own foundation to help orphans and underprivileged children in Vietnam, which will be a full circle moment for him and so many others he’s impacted along the way.
About MANSCAPED™:
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED is the global leader in men's grooming and hygiene below-the-waist. The product range includes only the best tools, formulations, and accessories for a simple, effective, and elevated male grooming routine. MANSCAPED offers a one-stop-shop at manscaped.com and direct-to-consumer shipping in more than 30 countries, spanning the United States, Canada, Australia, New Zealand, the United Kingdom, the European Union, Norway, and Switzerland. Select products and unique bundles can also be found on Amazon with Prime and pickup options available. Retail placement includes Target and Best Buy locations throughout the U.S., with further domestic and international retailers coming soon. For more information, visit the website or follow on Facebook, Instagram, Twitter, TikTok, YouTube, and Triller.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005280/en/
Contact information
Allison Frazier, Director of Public Relations – MANSCAPED, Inc.
allison@manscaped.com
925-216-2791
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
